restricting the use of Tasmar (tolcapone) due to reports of serious liver toxicity

The FDA and HPB are restricting the use of Tasmar (tolcapone) due to reports of serious liver toxicity...including three deaths.

Tasmar just came out last year. It's used to prolong the effect of levodopa in patients with advanced Parkinson's.

Now the FDA recommends limiting Tasmar to patients who can't take or don't respond to other Parkinson's drugs.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote